We see the unseen.

At Alexion, we see opportunities where others do not and we have the courage to explore what others believe is impossible. We see patients suffering from devastating diseases that are often overlooked. We see a pathway from innovative science to the delivery of breakthrough therapies.

Patients with these life-threatening diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people's lives depend on our work.


LATEST NEWS

 

Learn More About the PMPRB Hearing with Alexion Canada


CADTH Common Drug Review Patient Input

Patients living with a rare disease face many challenges and often live with little hope and have limited treatment options. Their experiences and perspectives are important to better understanding the disease. From now until November 23, 2017, there is an open call for patient input for the CADTH Common Drug Review of Kanuma (sebelipase alfa) for the treatment of lysosomal acid lipase deficiency (LAL-D). Individuals wishing to contribute to the patient submission should contact Andrew McFadyen of the Isaac Foundation and the Equal Access for Rare Disorders via email or website.
 

Seeing the Unseen for 25 Years

For 25 years, Alexion has seen opportunities where others have not. We have had the courage to explore what others believe is impossible. And we have forged a pathway from innovative science to breakthrough therapies for patients suffering from devastating diseases that had previously been overlooked. Learn more.